2E7A
 
 | |
5TSW
 | |
4MXV
 | | Structure of Lymphotoxin alpha bound to anti-LTa Fab | | Descriptor: | Lymphotoxin-alpha, anti-Lymphotoxin alpha antibody heavy chain, anti-Lymphotoxin alpha antibody light chain | | Authors: | Yin, J.P, Hymowitz, S.G. | | Deposit date: | 2013-09-26 | | Release date: | 2013-11-13 | | Last modified: | 2023-09-20 | | Method: | X-RAY DIFFRACTION (3.2 Å) | | Cite: | Dimerization of LT beta R by LT alpha 1 beta 2 is necessary and sufficient for signal transduction.
Proc.Natl.Acad.Sci.USA, 110, 2013
|
|
5Y9J
 | | BAFF in complex with belimumab | | Descriptor: | Tumor necrosis factor ligand superfamily member 13B, belibumab light chain, belimumab heavy chain | | Authors: | Heo, Y.-S, Shin, W. | | Deposit date: | 2017-08-25 | | Release date: | 2018-02-21 | | Last modified: | 2019-09-04 | | Method: | X-RAY DIFFRACTION (2.05 Å) | | Cite: | BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus.
Nat Commun, 9, 2018
|
|
4G3Y
 | | Crystal structure of TNF-alpha in complex with Infliximab Fab fragment | | Descriptor: | Tumor necrosis factor, infliximab Fab H, infliximab Fab L | | Authors: | Liang, S.Y, Dai, J.X, Guo, Y.J, Lou, Z.Y. | | Deposit date: | 2012-07-15 | | Release date: | 2013-03-27 | | Last modified: | 2013-08-07 | | Method: | X-RAY DIFFRACTION (2.6 Å) | | Cite: | Structural basis for treating tumor necrosis factor alpha (TNFalpha)-associated diseases with the therapeutic antibody infliximab
J.Biol.Chem., 288, 2013
|
|
5UUI
 | | Crystal Structure of Spin-Labeled T77C TNFa | | Descriptor: | S-[(1-oxyl-2,2,5,5-tetramethyl-2,5-dihydro-1H-pyrrol-3-yl)methyl] methanesulfonothioate, Tumor necrosis factor | | Authors: | Horanyi, P.S, Dranow, D.M, Ceska, T. | | Deposit date: | 2017-02-16 | | Release date: | 2017-08-02 | | Last modified: | 2024-01-17 | | Method: | X-RAY DIFFRACTION (1.4 Å) | | Cite: | Natural Conformational Sampling of Human TNF alpha Visualized by Double Electron-Electron Resonance.
Biophys. J., 113, 2017
|
|
5YOY
 | | Crystal structure of the human tumor necrosis factor in complex with golimumab Fv | | Descriptor: | Golimumab heavy chain variable region, Golimumab light chain variable region, Tumor necrosis factor | | Authors: | Ono, M, Horita, S, Sato, Y, Nomura, Y, Iwata, S, Nomura, N. | | Deposit date: | 2017-10-31 | | Release date: | 2018-05-09 | | Last modified: | 2023-11-22 | | Method: | X-RAY DIFFRACTION (2.727 Å) | | Cite: | Structural basis for tumor necrosis factor blockade with the therapeutic antibody golimumab
Protein Sci., 27, 2018
|
|
1OSG
 | | Complex between BAFF and a BR3 derived peptide presented in a beta-hairpin scaffold | | Descriptor: | BR3 derived PEPTIDE, MAGNESIUM ION, Tumor necrosis factor ligand superfamily member 13B | | Authors: | Gordon, N.C, Pan, B, Hymowitz, S.G, Yin, J.P, Kelley, R.F, Cochran, A.G, Yan, M, Dixit, V.M, Fairbrother, W.J, Starovasnik, M.A. | | Deposit date: | 2003-03-19 | | Release date: | 2003-05-27 | | Last modified: | 2023-08-16 | | Method: | X-RAY DIFFRACTION (3 Å) | | Cite: | BAFF/BLyS receptor 3 comprises a minimal TNF receptor-like module that encodes a highly focused ligand-binding site
Biochemistry, 42, 2003
|
|
3WD5
 | | Crystal structure of TNFalpha in complex with Adalimumab Fab fragment | | Descriptor: | Adalimumab Heavy Chain, Adalimumab Light Chain, Tumor necrosis factor | | Authors: | Hu, S, Liang, S.Y, Guo, Y.J, Lou, Z.Y. | | Deposit date: | 2013-06-06 | | Release date: | 2013-08-14 | | Last modified: | 2015-07-01 | | Method: | X-RAY DIFFRACTION (3.101 Å) | | Cite: | Comparison of the inhibition mechanisms of adalimumab and infliximab in treating tumor necrosis factor alpha-associated diseases from a molecular view
J.Biol.Chem., 288, 2013
|
|
4HT1
 | | Human TWEAK in complex with the Fab fragment of a neutralizing antibody | | Descriptor: | Tumor necrosis factor ligand superfamily member 12, chimeric antibody Fab | | Authors: | Lammens, A. | | Deposit date: | 2012-10-31 | | Release date: | 2013-06-12 | | Last modified: | 2017-11-15 | | Method: | X-RAY DIFFRACTION (2.498 Å) | | Cite: | Crystal Structure of Human TWEAK in Complex with the Fab Fragment of a Neutralizing Antibody Reveals Insights into Receptor Binding.
Plos One, 8, 2013
|
|
5WUX
 | | TNFalpha-certolizumab Fab | | Descriptor: | Tumor necrosis factor alpha, heavy, light | | Authors: | Heo, Y.S, Lee, J.U. | | Deposit date: | 2016-12-21 | | Release date: | 2017-06-07 | | Method: | X-RAY DIFFRACTION (2.9 Å) | | Cite: | Molecular Basis for the Neutralization of Tumor Necrosis Factor alpha by Certolizumab Pegol in the Treatment of Inflammatory Autoimmune Diseases
Int J Mol Sci, 18, 2017
|
|
3K48
 | | Crystal structure of APRIL bound to a peptide | | Descriptor: | Tumor necrosis factor ligand superfamily member 13, peptide | | Authors: | Hymowitz, S.G. | | Deposit date: | 2009-10-05 | | Release date: | 2009-11-24 | | Last modified: | 2023-09-06 | | Method: | X-RAY DIFFRACTION (2.8 Å) | | Cite: | Multiple novel classes of APRIL-specific receptor-blocking peptides isolated by phage display.
J.Mol.Biol., 396, 2010
|
|
6X83
 | |
6X82
 | | Crystal Structure of TNFalpha with isoquinoline compound 4 | | Descriptor: | 8-[4-(2-{5-[(4-methylpiperazin-1-yl)methyl]-2-(1H-pyrrolo[3,2-c]pyridin-3-yl)phenoxy}ethyl)phenyl]isoquinoline, Tumor necrosis factor | | Authors: | Longenecker, K.L, Stoll, V.S. | | Deposit date: | 2020-06-01 | | Release date: | 2021-01-13 | | Last modified: | 2023-10-18 | | Method: | X-RAY DIFFRACTION (2.75 Å) | | Cite: | Development of Orally Efficacious Allosteric Inhibitors of TNF alpha via Fragment-Based Drug Design.
J.Med.Chem., 64, 2021
|
|
6X86
 | | Crystal Structure of TNFalpha with indolinone compound 11 | | Descriptor: | 3-[(6-{2-[(3R)-4-(hydroxyacetyl)-3-methylpiperazin-1-yl]pyrimidin-5-yl}-2,2-dimethyl-3-oxo-2,3-dihydro-1H-indol-1-yl)methyl]pyridine-2-carbonitrile, Tumor necrosis factor | | Authors: | Longenecker, K.L, Stoll, V.S. | | Deposit date: | 2020-06-01 | | Release date: | 2021-01-13 | | Last modified: | 2023-10-18 | | Method: | X-RAY DIFFRACTION (2.93 Å) | | Cite: | Development of Orally Efficacious Allosteric Inhibitors of TNF alpha via Fragment-Based Drug Design.
J.Med.Chem., 64, 2021
|
|
3LKJ
 | | Small Molecule Inhibition of the TNF Family Cyokine CD40 Ligand Through a Subunit Fracture Mechanism | | Descriptor: | (2R)-{[(2'-[(biphenyl-3-ylmethyl)carbamoyl]-6'-{[(2R)-2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl]carbonyl}-6-{[(2R)-2-(1H-pyrrol-1-ylmethyl)pyrrolidin-1-yl]carbonyl}-4,4'-bipyridin-2-yl)carbonyl]amino}(cyclohexyl)ethanoic acid, 2-acetamido-2-deoxy-beta-D-glucopyranose, CD40 ligand | | Authors: | Silvian, L.F, Whitty, A. | | Deposit date: | 2010-01-27 | | Release date: | 2011-02-02 | | Last modified: | 2023-09-06 | | Method: | X-RAY DIFFRACTION (2.5 Å) | | Cite: | Small Molecule Inhibition of the TNF Family Cytokine CD40 Ligand through a Subunit Fracture Mechanism.
Acs Chem.Biol., 6, 2011
|
|
6X81
 | |
5L19
 | | Crystal Structure of a human FasL mutant | | Descriptor: | SULFATE ION, Tumor necrosis factor ligand superfamily member 6, ZINC ION | | Authors: | Liu, W, Bonanno, J.B, Almo, S.C. | | Deposit date: | 2016-07-28 | | Release date: | 2016-09-07 | | Last modified: | 2023-10-04 | | Method: | X-RAY DIFFRACTION (2 Å) | | Cite: | Crystal Structure of the Complex of Human FasL and Its Decoy Receptor DcR3.
Structure, 24, 2016
|
|
2O0O
 | | Crystal structure of TL1A | | Descriptor: | MAGNESIUM ION, TNF superfamily ligand TL1A | | Authors: | Jin, T.C, Kim, S, Guo, F, Howard, A.J, Zhang, Y.Z. | | Deposit date: | 2006-11-27 | | Release date: | 2007-10-30 | | Last modified: | 2023-08-30 | | Method: | X-RAY DIFFRACTION (3 Å) | | Cite: | X-ray crystal structure of TNF ligand family member TL1A at 2.1A.
Biochem.Biophys.Res.Commun., 364, 2007
|
|
5M2J
 | | Complex between human TNF alpha and Llama VHH2 | | Descriptor: | Anti-(ED-B) scFV, Tumor necrosis factor | | Authors: | Cambillau, C, Spinelli, S, Desmyter, A, de Haard, H. | | Deposit date: | 2016-10-13 | | Release date: | 2017-08-30 | | Last modified: | 2024-01-17 | | Method: | X-RAY DIFFRACTION (1.9 Å) | | Cite: | Bivalent Llama Single-Domain Antibody Fragments against Tumor Necrosis Factor Have Picomolar Potencies due to Intramolecular Interactions.
Front Immunol, 8, 2017
|
|
5M2M
 | | Complex between human TNF alpha and Llama VHH3 | | Descriptor: | Llama nanobody VHH3, Tumor necrosis factor | | Authors: | Cambillau, C, Spinelli, S, Desmyter, A, de Haard, H. | | Deposit date: | 2016-10-13 | | Release date: | 2017-08-30 | | Last modified: | 2024-01-17 | | Method: | X-RAY DIFFRACTION (2.3 Å) | | Cite: | Bivalent Llama Single-Domain Antibody Fragments against Tumor Necrosis Factor Have Picomolar Potencies due to Intramolecular Interactions.
Front Immunol, 8, 2017
|
|
2ZPX
 | |
2ZJC
 | | TNFR1 selectve TNF mutant; R1-6 | | Descriptor: | GLYCEROL, Tumor necrosis factor | | Authors: | Mukai, Y, Yamagata, Y, Tsutsumi, Y. | | Deposit date: | 2008-03-05 | | Release date: | 2009-01-20 | | Last modified: | 2023-11-01 | | Method: | X-RAY DIFFRACTION (2.5 Å) | | Cite: | Structure-Function Relationship of Tumor Necrosis Factor (TNF) and Its Receptor Interaction Based on 3D Structural Analysis of a Fully Active TNFR1-Selective TNF Mutant
J.Mol.Biol., 385, 2009
|
|
3B9I
 | |
2Q8O
 | |
